Endometrial Markers in Autoimmune Diseases

Status Active, not recruiting

Clinical Trial Summary

Autoimmune diseases cause a decreased endometrial receptivity during the implantation window, most likely changing the endometrial cytokines pattern due to dysregulation of the inflammatory processes.Therefore, endometrial cytokine profiles will be compared in women with autoimmune disease and normal, fertile women. The collected endometrial tissue and blood samples will be examined for the cytokines profiling using commercially available ELISA kits. The sample size was calculated choosing, as primary outcome, changes in endometrial LIF concentration between the disease and control Group, which is our main goal. Given a type I error of 5%, a maximum of 21 women are needed for each Group to reach the desired power of 80% to detect the least changes in concentrations.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03843034
Study type	Observational
Source	Odense University Hospital
Contact
Status	Active, not recruiting
Phase
Start date	February 18, 2019
Completion date	December 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04078698` - Documentation of the Safety and Effectiveness Profile of the IgG Immunoadsorber GLOBAFFIN® in Clinical Routine	N/A
Recruiting	`NCT04039763` - RT-CGM in Young Adults at Risk of DKA	N/A
Recruiting	`NCT05670301` - Flemish Joint Effort for Biomarker pRofiling in Inflammatory Systemic Diseases	N/A
Completed	`NCT03266172` - A Study to Compare the Pharmacokinetics (PK) of GSK2982772 Following Administration of Different Modified Release (MR) Formulations in Capsule and MR Tablet Formulations Relative to an Immediate Release (IR) Tablet Formulation and to Check the PK of MR Formulation in Capsule Following Repeat Doses	Phase 1
Completed	`NCT03649412` - A Study to Investigate the Pharmacokinetics (PK) of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772	Phase 1
Recruiting	`NCT04561557` - Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System	Early Phase 1
Completed	`NCT03173144` - Chronic Inflammatory Disease, Lifestyle and Treatment Response
Completed	`NCT00975936` - Phase 0 Microdose Study	Phase 1
Not yet recruiting	`NCT05969821` - Clonal Hematopoiesis of Immunological Significance
Completed	`NCT01210716` - Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device	Phase 3
Completed	`NCT00820469` - Study of the Influence of Plasma Exchange on the Pharmacokinetics of Rituximab	Phase 4
Completed	`NCT01953523` - Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions	N/A
Withdrawn	`NCT03239600` - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Proof of Mechanism of GSK2618960 in Primary Sjögren's Syndrome (pSS)	Phase 2
Completed	`NCT04872257` - Oral Vitamin D Supplementation Combined With Phototherapy as a Treatment for Vitiligo	N/A
Recruiting	`NCT06019611` - Epidural Stimulation in Multiple Sclerosis	N/A
Recruiting	`NCT05030779` - A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus	Early Phase 1
Not yet recruiting	`NCT03899298` - Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions	Phase 1
Completed	`NCT04005456` - Personalized Lifestyle Intervention for Improving Functional Health Outcomes Using N-of-1 Tent-Umbrella-Bucket Design	N/A
Recruiting	`NCT05085444` - A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma	Early Phase 1
Recruiting	`NCT05853835` - First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641	Phase 1